Please don't hesitate to contact us if you have any questions or other inquiries.

A new chapter in the Nordic Bioscience history unveils

KKR's investment will support Nordic Bioscience with its ambitious growth goals: Global expansion of R&D services, diagnostics platform, leading patent portfolio, and drug development.


Nordic Bioscience has established itself as the world's most experienced extracellular matrix (ECM) company through more than 25 years of dedicated research and development. The ECM is the non-cellular component of all tissues and organs. When degraded or formed, tissue-specific fragments are released into the blood and can be used as biomarkers (indicators of biological changes). Nordic Bioscience specializes in blood-based biomarkers that measure the degradation or formation of ECM fragments. In addition, this knowledge can be used to identify new drug candidates, diagnose patients and evaluate the effect of existing drugs and drug candidates.

Nordic Bioscience holds more than 150 patents and has published over 500 scientific papers in leading journals. The company has partnered with the world's largest pharmaceutical companies to develop new drugs in various disease areas (fibrosis, oncology, diabetes and cardiovascular) and collaborates with leading diagnostic companies to use their novel biomarkers for diagnostic purposes. In addition, Nordic Bioscience serves a growing international client base of biotech, CRO and pharmaceutical companies with analysis of preclinical and clinical data in its CAP certified laboratory.

KKR is a fantastic addition to Nordic Bioscience as the company has a strong track record of supporting healthcare companies and has experience in the pharmaceutical and drug development industry. KKR has helped hundreds of companies with their growth ambitions and has offices around the world.

"I am pleased to welcome KKR as a valued investor to the Nordic Bioscience team and to have their support as we expand our strategy to bring innovative novel diagnostic biomarkers and drug candidates to market for the benefit of patients. Our fast-moving customers have high expectations, and KKR's investment will drive Nordic Bioscience to continue to meet those expectations. The core of Nordic Bioscience is the collaboration between our team, with our partners and customers and now also with KKR," said Morten Karsdal, CEO of Nordic Bioscience.

Read more about the investment on or on KKR's website:

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.